Neutral Result With Novel Agent in Diabetic Cardiomyopathy Neutral Result With Novel Agent in Diabetic Cardiomyopathy
The ARISE-HF trial testing aldose reductase inhibition in asymptomatic diabetic cardiomyopathy did not meet its endpoint but hints at a mechanism that might prevent it.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 16, 2024 Category: Cardiology Tags: Cardiology News Source Type: news
Single-Dose Zilebesiran Cuts BP Out to 6 Months: KARDIA-2 Single-Dose Zilebesiran Cuts BP Out to 6 Months: KARDIA-2
This phase 2 study supports the potential for combining biannual dosing of zilebesiran with standard-of-care antihypertensives to achieve additive blood pressure reductions.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 15, 2024 Category: Cardiology Tags: Cardiology News Source Type: news
EMPACT-MI: Another SGLT2 Inhibitor Miss Post-MI EMPACT-MI: Another SGLT2 Inhibitor Miss Post-MI
Empagliflozin added to standard care did not improve outcomes in post-MI patients at risk for heart failure. John Mandrola, MD, sees the diminishing returns for add-on drugs as positive for patients.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 12, 2024 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Semaglutide Benefits in HFpEF Step Beyond Weight Loss Semaglutide Benefits in HFpEF Step Beyond Weight Loss
Drs Pi ña and Kosiborod discuss semaglutide in obesity-related HF with and without diabetes. Both STEP HFpEF trials show similar HF benefits despite less weight loss in patients with diabetes.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 12, 2024 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Novel Drug Shows a Signal to Improve nHCM Novel Drug Shows a Signal to Improve nHCM
In the phase 2 IMPROVE-HCM trial, cardiac mitotrope ninerafaxstat was safe, with a signal of improved cardiac function in moderate nonobstructive hypertrophic cardiomyopathy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 12, 2024 Category: Cardiology Tags: Cardiology News Source Type: news
Coronary Sinus Reducer an Option for Intractable Angina? Coronary Sinus Reducer an Option for Intractable Angina?
A coronary sinus reducer met one of two primary endpoints by reducing refractory angina in the ORBITA-COSMIC trial, but not the second, improvement in perfusion.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 12, 2024 Category: Cardiology Tags: Cardiology News Source Type: news
Extended Zerlasiran Data Show Sustained Lp(a) Reduction Extended Zerlasiran Data Show Sustained Lp(a) Reduction
The experimental siRNA agent led to prolonged Lp(a) reduction of more than 90%, extended data from the phase 1 trial show, supporting the move to phases 2 and 3 trials.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 12, 2024 Category: Cardiology Tags: Cardiology News Source Type: news
Reduce Sitting Time to Lower Blood Pressure Reduce Sitting Time to Lower Blood Pressure
Dr JoAnn Manson comments on the significance of a randomized trial showing the benefits of reduced sitting time in older adults.Medscape Ob/Gyn (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 11, 2024 Category: Cardiology Tags: Ob/Gyn & Women ' s Health Commentary Source Type: news
Preventive Coronary Stents: Not There Yet Preventive Coronary Stents: Not There Yet
The PREVENT trial on stenting stable plaques deemed vulnerable by imaging criteria suggests a benefit over medical therapy alone. John Mandrola, MD, finds it provocative but not yet ready to act on.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 11, 2024 Category: Cardiology Tags: Cardiology Commentary Source Type: news
New Data Question Beta-Blockers Post-MI With Preserved EF New Data Question Beta-Blockers Post-MI With Preserved EF
In patients who had revascularization after an acute MI and had a preserved EF, long-term beta-blocker use showed no benefit compared with no beta-blockers, in REDUCE-AMI.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 11, 2024 Category: Cardiology Tags: Cardiology News Source Type: news
Preventive PCI for Vulnerable Plaques Reduces Cardiac Events Preventive PCI for Vulnerable Plaques Reduces Cardiac Events
Preventive PCI plus optimal medical therapy reduced cardiac events and death in patients with non –flow-limiting coronary plaques vs medical therapy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 10, 2024 Category: Cardiology Tags: Cardiology Source Type: news
Web-Based App Allows Nonprescription Statin Use Web-Based App Allows Nonprescription Statin Use
Use of an app to determine eligibility for a statin without a prescription could expand treatment and lead to a reduction in CV events, the TACTiC trial suggests.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 9, 2024 Category: Cardiology Tags: Cardiology Source Type: news
Dollars, Points Help CV Patients Increase Activity Dollars, Points Help CV Patients Increase Activity
Modest financial incentives and gamification encouraged people with cardiovascular risks to meaningfully increase daily step counts over 18 months, in the BE ACTIVE trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 8, 2024 Category: Cardiology Tags: Cardiology Source Type: news
Beta-Blockers Post-MI Past Their Expiration Date: REDUCE-AMI Beta-Blockers Post-MI Past Their Expiration Date: REDUCE-AMI
REDUCE-AMI showed no benefit for routine beta-blockers post –MI in patients with normal ejection fraction. John Mandrola, MD, asks: Does evidence-based medicine need expiration dates?theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 8, 2024 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Poop Doesn't Lie: What Fecal'Forensics' Tells Us About Diet Poop Doesn't Lie: What Fecal'Forensics' Tells Us About Diet
Innovative work from Duke University could change how scientists conduct nutritional research and how clinicians assess their patients ' diets.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 8, 2024 Category: Cardiology Tags: Gastroenterology Source Type: news
